Immuno-Oncology | Specialty

The immuno-oncology condition center is a comprehensive resource for clinical news and expert insights on immuno-oncology. Read more at OncLive.

Nivolumab Plus Ipilimumab Wins European Approval for MSI-H/dMMR mCRC

December 23rd 2024

Nivolumab plus ipilimumab has been approved in Europe for the frontline treatment of adult patients with MSI-H or dMMR metastatic colorectal cancer.

Nivolumab/CCRT Followed by Nivolumab/Ipilimumab Misses PFS End Point in Select Stage III NSCLC

December 23rd 2024

CheckMate 73L missed its primary end point of PFS in advanced unresectable stage III non–small cell lung cancer.

Perioperative Pembrolizumab Regimen Upholds Survival Benefit in Resectable NSCLC

December 21st 2024

The neoadjuvant/adjuvant pembrolizumab and chemotherapy combination was approved by the FDA in October 2023 for use in this patient population.

FDA Approves Cosibelimab for Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma

December 13th 2024

The FDA has approved cosibelimab-ipdl for the treatment of adults with metastatic or locally advanced cutaneous squamous cell carcinoma who are not candidates for curative surgery or radiation.

Pembrolizumab/Chemo, Followed by Olaparib Maintenance, Boosts PFS in Advanced Ovarian Cancer

December 9th 2024

Pembrolizumab plus chemotherapy, followed by olaparib with or without bevacizumab, improved PFS in advanced ovarian cancer.

FS118 Showcases Modest Efficacy in Relapsed/Refractory DLBCL

December 8th 2024

FS118, an investigational LAG-3/PD-L1 bispecific antibody, demonstrated an encouraging objective response rate in the relapsed/refractory DLBCL setting.

Immunotherapy Redefines Standard of Care for Frontline Advanced Endometrial Cancer

December 5th 2024

Monica H. Vetter, MD, discusses the integration of immunotherapy into chemotherapy regimens for frontline advanced endometrial cancer.

Revisit Every OncLive On Air Episode From November 2024

December 2nd 2024

In case you missed any, read a recap of every episode of OncLive On Air that aired in November 2024.

Discussions Swirl on the Role of PD-1 Inhibitors for Gastric/GEJ/ESCC Cancers With 1%-10% PD-L1 Expression

November 27th 2024

Nataliya Uboha, MD, PhD, and Robert Albert Anders, MD, PhD, unpack the unfavorable risk-benefit profile of PD-1 inhibitors in patients with certain PD-L1–negative gastrointestinal cancers and discussions from a recent ODAC meeting.

The OncFive: Top Oncology Articles for the Week of 11/17

November 23rd 2024

Zanidatamab scores approval for HER2+ biliary tract cancer, Versamune HPV is under exploration in HPV16+ head and neck squamous cell carcinoma, and more.

Versamune HPV Could Bolster Long-Term Efficacy With Pembrolizumab in HPV16-Driven HNSCC

November 18th 2024

Experts discuss the ongoing investigation of Versamune HPV plus pembrolizumab and its potential effect on outcomes in first-line HPV16-driven HNSCC.

The OncFive: Top Oncology Articles for the Week of 11/10

November 16th 2024

New datopotamab deruxtecan BLA in NSCLC filed to FDA, radiopharmaceutical meets rPFS end point in PSMA+ prostate cancer, and more.

Data for Nivolumab Plus AVD Could Help Harmonize Treatment of Older and Younger Advanced-Stage Hodgkin Lymphoma

November 14th 2024

Alex F. Herrera, MD, discusses long-term data from nivolumab plus AVD in advanced-stage Hodgkin lymphoma.

IMA203 Produces Responses in Heavily Pretreated Advanced Melanoma, Other Solid Tumors

November 11th 2024

The investigational PRAME-targeted T-cell therapy IMA203 generated responses in melanoma and other solid tumors,

E-602 Plus Cemiplimab Elicits Preliminary Antitumor Activity, Is Safe in PD-(L)1–Resistant Solid Tumors

November 11th 2024

E-602 plus cemiplimab elicited preliminary antitumor activity and had a tolerable safety profile in PD-(L)1–resistant solid tumors.

Post Hoc Analysis Reveals Potential Serum Glycoproteomic Biomarkers for Nivolumab/Cabozantinib in Advanced RCC

November 9th 2024

David A. Braun, MD, PhD, discusses the potential for protein glycosylation as a biomarker to predict nivolumab/cabozantinib responses in advanced RCC.

Immune Profile Score Algorithmic Test Is Now Available to Help Inform Checkpoint Inhibitor Use in Cancer

November 7th 2024

The Immune Profile Score algorithmic test is now available for clinical use as a prognostic tool for immune checkpoint inhibitors in solid tumors.

DK210 (EGFR) Induces Immune Response Without Increased CRS or Regulatory T Cells in Solid Tumors

November 7th 2024

DK210 (EGFR) showed evidence of wild-type IL-2 signaling, CRS mitigation, and immune response signaling in patients with solid tumors.

OncLive’s October Roundup of Key FDA Approvals in Oncology

November 5th 2024

Here is your snapshot of all therapeutic options that the FDA approved in October 2024 spanning tumor types.

The OncFive: Top Oncology Articles for the Week of 10/20

October 26th 2024

FDA accepts rivoceranib/camrelizumab NDA for review in HCC, acalabrutinib triplet yields responses in untreated mantle cell lymphoma, and more from OncLive this week.